Published by ChinaMNC · Qiongshan

China’s 15th Five-Year Plan for the Pharmaceutical Industry: What Foreign Founders Need to Know

A practical briefing for foreign founders on China’s Pharmaceutical Industry Development 15th Five-Year Plan, covering the 2030 targets, priority tasks, and policy coordination relevant to registering and operating a company in China’s biopharma sector.

Why the Plan Matters for Foreign Founders

China’s Ministry of Industry and Information Technology, together with nine other departments, has issued the Pharmaceutical Industry Development 15th Five-Year Plan (MIIT Joint Regulation [2026] No. 210). For foreign founders considering a China entity in biopharma, medical devices, or related supply chains, the plan signals where policy attention, infrastructure, and regulatory coordination are heading through 2030. It is a planning document, not a licence or an incentive scheme, so founders should read it as a map of national priorities rather than a guarantee of specific treatment.

The plan treats pharmaceuticals as a strategic emerging industry tied to national security and public health, and as a focus area for cultivating “new quality productive forces.” That framing matters for founders because it explains why the sector receives coordinated attention across industry, health, drug regulation, medical insurance, and science and technology portfolios.

What the Previous Plan Achieved

The source document reviews results since the 14th Five-Year Plan. According to the government’s interpretation, value-added output of above-designated-size pharmaceutical enterprises grew at an average annual rate of 4.1% and held a steady share of about 3.6% of total above-designated-size industrial value-added output. It also states that 230 innovative drugs and 292 innovative medical devices reached the market, and that China ranks second globally by number of new drugs under research. The document further notes breakthroughs in high-end pharmaceutical excipients, reagents and consumables, and raw materials and core components for medical devices, as well as rapid development and expanded production of vaccines, drugs, and devices across multiple technology routes during major epidemic response.

For founders, these points describe an established domestic industrial base and supply chain depth. They do not by themselves create market access rights, but they indicate where local suppliers, contract manufacturers, and research partners may be available.

Context for the 2026–2030 Period

The plan identifies the 15th Five-Year Plan period as a critical window for building a manufacturing powerhouse and a Healthy China, and as an opportunity period for structural adjustment and innovation-driven transformation. It references the 2026 Government Work Report’s call to accelerate development of biomedicine as an emerging pillar industry. It also cites population ageing and a shift in health demand toward full life-cycle management as reasons for stronger top-level design.

Headline Goals to 2030

The plan sets out qualitative goals for 2030: biopharmaceutical R&D and application remaining among the world’s leaders; systemic breakthroughs in key core technologies in priority fields; digital and intelligent enablement across the whole industrial chain; a precision medicine system supporting comprehensive prevention and treatment of major diseases; a maturing ecosystem for coordinated factors; solid production and supply guarantees; and a marked rise in core competitiveness and international influence, with deeper integration into global pharmaceutical innovation networks.

It also lists expected indicators for the period. Founders should note that these are anticipated targets, not commitments to individual companies:

• Scale and efficiency: operating revenue of above-designated-size pharmaceutical enterprises exceeding RMB 3.5 trillion; innovative drug industry scale growing at an average annual rate of 20% or more; at least five products with annual global sales above USD 1 billion.
• Innovation: average R&D intensity of listed pharmaceutical enterprises reaching 10% or more per year; pipelines of new drugs in first clinical trials and the number of approved innovative drugs ranking among the world’s leaders; first-in-class drugs accounting for 25% or more globally; at least 200 innovative medical devices approved.
• Enterprise and cluster development: 50 pharmaceutical enterprises with annual revenue above RMB 10 billion; 20 pharmaceutical industrial parks at the RMB 100 billion level.

Eight Priority Areas and 25 Tasks

The plan organises 25 key tasks under eight headings. In practical terms for a foreign founder, they point to the following areas of policy focus:

• Original innovation and platforms: strengthening early-stage research, using industrial innovation platforms, and developing innovative drugs and devices, including frontier technologies.
• Industrial base and resilience: reinforcing foundations, consolidating competitive advantages, and cultivating new growth drivers.
• Digital and intelligent transformation: applying artificial intelligence, advancing digitalisation, and improving green manufacturing.
• Precision prevention, diagnosis, and treatment: building products and ecosystems around precision approaches.
• Efficient factor ecosystems: smoother clinical translation, engineering scale-up, and industrial coordination.
• Value creation: health, social, and cultural value of the industry.
• Supply and accessibility: diversified safeguards, quality supply of essential medicines and devices, and improved access.
• International cooperation: competitiveness, cooperation capacity, and market attractiveness.

Implementation and Regulatory Coordination

The Ministry of Industry and Information Technology says it will coordinate implementation through inter-ministerial mechanisms covering strategic planning, major projects, and support policies. It names coordination across industry, science and technology, regulation, healthcare, medical insurance, finance, and talent. It also refers to optimising review and approval mechanisms, improving pricing, payment, and use policies, strengthening public science communication, and supporting talent and industry organisations.

For foreign founders, these references suggest that market entry and ongoing operations will involve multiple agencies, not a single approval. Company registration, product registration, reimbursement, and talent policies may each follow separate tracks. The plan does not specify new foreign investment permissions or tax treatments, so founders should verify current requirements with the relevant authorities or professional advisers before committing to a structure.

Practical Takeaways

• Treat the plan as a signal of long-term policy direction in biopharma and medical devices, not as an individual entitlement.
• Map your China entity’s activities against the eight priority areas to identify where coordination mechanisms may be relevant.
• Expect multi-agency processes covering registration, regulation, pricing, and payment; budget time and local expertise accordingly.
• Monitor implementing measures from the ministries named in the plan, since specific rules will follow at a later stage.

This summary is based on information published by the relevant Chinese government website and is general information, not legal or tax advice.